Csquare, a leading digital infrastructure platform, will release its financial results for the third quarter of 2026 on November 9 after market close. The company will hold a conference call at 5:00 PM EDT the same day to discuss the results for the period ending September 30, 2026. Investors can access the live webcast and replay through the company's Investor Relations site. This update is important as Csquare operates key data centers across North America and the UK, supporting critical tech infrastructure including hybrid cloud and AI applications.
Csquare's upcoming third-quarter 2026 earnings release and conference call provide context for readers interested in tech sector activity. For readers following Technology-sector US stocks on Pluang, 81 out of 150 stocks rose while 67 fell as of Oct 20, 2026 03:01 WIB. Notable movers include Fastly Inc (FSLY) at USD 22.45 with a 1-day change of -10.45%, GoPro Inc (GPRO) at USD 1.03 down 10.43%, and Mongodb Inc (MDB) at USD 336.50 down 8.18%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
